Kodiak Sciences Inc KOD

NAS: KOD | ISIN: US50015M1099   30/04/2025
4,360 USD (+4,81%)
(+4,81%)   30/04/2025
Grafiek Kodiak Sciences Inc Grafiek Kodiak Sciences Inc

Kodiak Sciences Inc in het nieuws

27 maart 2025 · Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results · Persbericht

10 maart 2025 · Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy · Persbericht

14 augustus 2024 · Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results · Persbericht

29 mei 2024 · Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences · Persbericht

15 mei 2024 · Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results · Persbericht

14 mei 2024 · Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy · Persbericht

2 mei 2024 · Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform · Persbericht

28 maart 2024 · Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results · Persbericht

26 maart 2024 · Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 · Persbericht

30 januari 2024 · Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting · Persbericht

Profiel Kodiak Sciences Inc

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Werknemers: 101

Mijn selecties